NL-OMON26185
Recruiting
Not Applicable
Adalimumab drug optimisation in rheumatoid arthritis using therapeutic drug monitoring (ADDORA): multi-centre open label randomised controlled trail
Reade Rheumatology Research Institute0 sites267 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Reade Rheumatology Research Institute
- Enrollment
- 267
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •Rheumatoid arthritis patient, according to ACR 1987 or ACR/EULAR 2010 criteria;
- •Starting adalimumab as the first biological therapy
- •Who has agreed to participate (written informed consent);
- •Age 18 years or older.
Exclusion Criteria
- •Scheduled surgery during the follow\-up of the study or other pre\-planned reasons for treatment discontinuation;
- •Life expectancy shorter than follow\-up period of the study;
- •Other disease that might flare if adalimumab is tapered like psoriasis, inflammatory bowel disease.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Adalimumab dose optimization in rheumatoid arthritis using drugconcentration in blood (ADDORA): multi-center open label randomizedcontrolled trailEUCTR2019-001554-25-NLReade267
Recruiting
Not Applicable
Adalimumab dose optimisation in rheumatoid arthritis using therapeutic drug monitoring (ADDORA): multi-centre open label randomised controlled trailNL-OMON47985Jan van Breemen Instituut267
Active, not recruiting
Phase 1
Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and soluble biomarkers.Whole-Body MRI in Rheumatoid Arthritis Protocol (WRAP)Reumatoid artritisMedDRA version: 12.1Level: LLTClassification code 10003268Term: Arthritis rheumatoidEUCTR2009-014394-41-DKHvidovre Hospital
Recruiting
Phase 4
Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug MonitoringRheumatoid ArthritisNCT04194827Reade Rheumatology Research Institute267
Completed
Phase 4
Predictors of the Response to Adalimumab in Rheumatoid ArthritisRheumatoid ArthritisNCT00234234University Hospital, Rouen200